Cantor Fitzgerald Comments on MNMD FY2026 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) – Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan anticipates that the company will post earnings per share of ($1.72) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Mind Medicine (MindMed)’s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD) last released its earnings results on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.01.

A number of other research firms also recently commented on MNMD. Chardan Capital reissued a “buy” rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 9th. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, March 7th. Finally, Robert W. Baird reduced their target price on Mind Medicine (MindMed) from $27.00 to $16.00 and set an “outperform” rating for the company in a report on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $25.50.

Mind Medicine (MindMed) Price Performance

Mind Medicine (MindMed) stock opened at $7.40 on Tuesday. Mind Medicine has a one year low of $4.70 and a one year high of $10.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 9.00 and a current ratio of 9.00. The business has a fifty day moving average of $6.52 and a two-hundred day moving average of $6.96. The company has a market cap of $559.09 million, a P/E ratio of -3.27 and a beta of 2.52.

Institutional Trading of Mind Medicine (MindMed)

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MNMD. SG Americas Securities LLC increased its position in Mind Medicine (MindMed) by 48.8% during the 4th quarter. SG Americas Securities LLC now owns 24,406 shares of the company’s stock worth $170,000 after purchasing an additional 8,004 shares in the last quarter. Rhumbline Advisers increased its position in Mind Medicine (MindMed) by 5.1% during the 4th quarter. Rhumbline Advisers now owns 100,695 shares of the company’s stock worth $701,000 after purchasing an additional 4,868 shares in the last quarter. Bank of New York Mellon Corp increased its position in Mind Medicine (MindMed) by 5.4% during the 4th quarter. Bank of New York Mellon Corp now owns 200,121 shares of the company’s stock worth $1,393,000 after purchasing an additional 10,338 shares in the last quarter. Oppenheimer & Co. Inc. increased its position in Mind Medicine (MindMed) by 25.1% during the 4th quarter. Oppenheimer & Co. Inc. now owns 65,541 shares of the company’s stock worth $456,000 after purchasing an additional 13,160 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Mind Medicine (MindMed) during the 4th quarter worth about $111,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Insider Transactions at Mind Medicine (MindMed)

In related news, CEO Robert Barrow sold 21,208 shares of Mind Medicine (MindMed) stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total transaction of $142,941.92. Following the completion of the sale, the chief executive officer now owns 856,556 shares in the company, valued at approximately $5,773,187.44. This trade represents a 2.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Daniel Karlin sold 6,836 shares of Mind Medicine (MindMed) stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $6.74, for a total value of $46,074.64. Following the sale, the insider now owns 446,177 shares of the company’s stock, valued at approximately $3,007,232.98. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. Insiders sold 30,391 shares of company stock valued at $204,835 in the last 90 days. 2.45% of the stock is currently owned by insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.